Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.
2.

Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies.

Pendergrass SA, Lemaire R, Francis IP, Mahoney JM, Lafyatis R, Whitfield ML.

J Invest Dermatol. 2012 May;132(5):1363-73. doi: 10.1038/jid.2011.472. Epub 2012 Feb 9.

3.

Emerging targets for the treatment of scleroderma.

Leask A.

Expert Opin Emerg Drugs. 2012 Jun;17(2):173-9. doi: 10.1517/14728214.2012.678833. Epub 2012 Apr 25. Review.

PMID:
22533795
4.

Molecular subsets in the gene expression signatures of scleroderma skin.

Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK, Whitfield ML.

PLoS One. 2008 Jul 16;3(7):e2696. doi: 10.1371/journal.pone.0002696. Erratum in: PLoS ONE. 2008;3(10). doi: 10.1371/annotation/05bed72c-c6f6-4685-a732-02c78e5f66c2.

5.

A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity.

Sargent JL, Milano A, Bhattacharyya S, Varga J, Connolly MK, Chang HY, Whitfield ML.

J Invest Dermatol. 2010 Mar;130(3):694-705. doi: 10.1038/jid.2009.318. Epub 2009 Oct 8.

6.

Egr-ly awaiting a "personalized medicine" approach to treat scleroderma.

Leask A.

J Cell Commun Signal. 2012 Jun;6(2):111-3. doi: 10.1007/s12079-012-0160-8. Epub 2012 Feb 15.

7.

N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma.

Dziadzio M, Usinger W, Leask A, Abraham D, Black CM, Denton C, Stratton R.

QJM. 2005 Jul;98(7):485-92. Epub 2005 Jun 13.

PMID:
15955800
8.

Analysis of the 5' flanking region of the interleukin 10 gene in patients with systemic sclerosis.

Crilly A, Hamilton J, Clark CJ, Jardine A, Madhok R.

Rheumatology (Oxford). 2003 Nov;42(11):1295-8. Epub 2003 Jul 16.

PMID:
12867583
9.

MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma.

Zhu H, Li Y, Qu S, Luo H, Zhou Y, Wang Y, Zhao H, You Y, Xiao X, Zuo X.

J Clin Immunol. 2012 Jun;32(3):514-22. doi: 10.1007/s10875-011-9647-y. Epub 2012 Feb 4.

PMID:
22307526
10.

Adiponectin expression is decreased in the involved skin and sera of diffuse cutaneous scleroderma patients.

Arakawa H, Jinnin M, Muchemwa FC, Makino T, Kajihara I, Makino K, Honda N, Sakai K, Fukushima S, Ihn H.

Exp Dermatol. 2011 Sep;20(9):764-6. doi: 10.1111/j.1600-0625.2011.01310.x. Epub 2011 May 25.

PMID:
21615510
11.

Ciprofloxacin utility as antifibrotic in the skin of patients with scleroderma.

Rubén EC, Manuel VR, Agustín OR, Huerta M, Antonio FM, Iván DE.

J Dermatol. 2010 Apr;37(4):323-9. doi: 10.1111/j.1346-8138.2010.00826.x.

PMID:
20507401
12.

[Acral scleroderma presenting simultaneously with small-cell bronchial carcinoma: a paraneoplastic disease?].

Merkl J, Poppert H, Hein R, Ring J.

J Dtsch Dermatol Ges. 2005 Feb;3(2):117-9. German.

PMID:
16351015
13.

HLA markers for susceptibility and expression in scleroderma.

Gladman DD, Kung TN, Siannis F, Pellett F, Farewell VT, Lee P.

J Rheumatol. 2005 Aug;32(8):1481-7.

PMID:
16078323
14.

MicroRNA-21 in scleroderma fibrosis and its function in TGF-β-regulated fibrosis-related genes expression.

Zhu H, Luo H, Li Y, Zhou Y, Jiang Y, Chai J, Xiao X, You Y, Zuo X.

J Clin Immunol. 2013 Aug;33(6):1100-9. doi: 10.1007/s10875-013-9896-z. Epub 2013 May 9. Erratum in: J Clin Immunol. 2013 Aug;33(6):1143-4.

PMID:
23657402
15.

Single-nucleotide polymorphisms in the SPARC gene are not associated with susceptibility to scleroderma.

Lagan AL, Pantelidis P, Renzoni EA, Fonseca C, Beirne P, Taegtmeyer AB, Denton CP, Black CM, Wells AU, du Bois RM, Welsh KI.

Rheumatology (Oxford). 2005 Feb;44(2):197-201. Epub 2004 Nov 16.

PMID:
15546965
16.

Expression analysis of multiple microRNAs in each patient with scleroderma.

Koba S, Jinnin M, Inoue K, Nakayama W, Honda N, Makino K, Kajihara I, Makino T, Fukushima S, Ihn H.

Exp Dermatol. 2013 Jul;22(7):489-91. doi: 10.1111/exd.12173.

PMID:
23800063
17.

Phototherapy: a promising treatment option for skin sclerosis in scleroderma?

Sunderkötter C, Kuhn A, Hunzelmann N, Beissert S.

Rheumatology (Oxford). 2006 Oct;45 Suppl 3:iii52-iii54. Review. Erratum in: Rheumatology (Oxford). 2008 Feb;47(2):234-5.

PMID:
16987838
18.

Systemic and cell type-specific gene expression patterns in scleroderma skin.

Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, McCalmont TH, Brown PO, Botstein D, Connolly MK.

Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12319-24. Epub 2003 Oct 6.

19.

Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies.

Fett N.

Clin Dermatol. 2013 Jul-Aug;31(4):432-7. doi: 10.1016/j.clindermatol.2013.01.010. Review.

PMID:
23806160
20.

Anti-cyclic citrullinated peptide antibodies in scleroderma patients.

Polimeni M, Feniman D, Skare TS, Nisihara RM.

Clin Rheumatol. 2012 May;31(5):877-80. doi: 10.1007/s10067-011-1930-z. Epub 2012 Jan 4.

PMID:
22215120

Supplemental Content

Support Center